ILMN · NASDAQ · STOCK
Illumina (ILMN) Stock Analysis
$278.08
52W $88.00 – $309.35
53/100
$42.09B
51.4
1.42
Is ILMN Bullish or Bearish?
Mixed.
Innellis AI committee rates Illumina, Inc. (ILMN) Watch with a composite score of 53/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +7.22 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -12.78 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- ROE of 31.1% shows genuine earnings power backing the valuation — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- P/E of 49.3 is expensive by classic value standards — Value
- Price-to-book of 7.5x prices in significant intangible value — Value
- EPS declining -31.9% YoY despite any revenue growth — Growth
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 84 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 33.7% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
53/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 81%
of 192 Healthcare peers
Value Analyst
neutral
42
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 31.1% shows genuine earnings power backing the valuation
− P/E of 49.3 is expensive by classic value standards
Growth Analyst
neutral
56
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ 5 consecutive earnings beats -- consistent execution
− EPS declining -31.9% YoY despite any revenue growth
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst
bearish
35
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 33.7% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 52.8 to 52.8.
- New bearish signals: 3 appeared.
- Bearish pressure eased: 3 signal(s) disappeared.
Analyst-level changes:
- Risk Analyst: +1 bearish signal(s).
- Technical Analyst: +1 bearish signal(s).
- Value Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
60.6
Neutral
MACD Histogram
-0.646
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Support
$260.69
Resistance
$371.05
Bollinger %B
0.73
Inside Bands
Price vs Moving Averages
EMA 9
$270.77
Above
EMA 21
$257.80
Above
EMA 50
$233.49
Above
EMA 200
$178.24
Above
Fundamental Analysis
Valuation
33
Growth
87
Profitability
98
Financial Health
82
Cash Flow
70
Valuation
P/E Ratio
51.4×
P/B Ratio
14.80×
PEG Ratio
-1.62
Dividend Yield
0.00%
52W High
$309.35
52W Low
$88.00
Quality & Growth
ROE
3121.6%
ROA
1279.3%
Gross Margin
6679.3%
Operating Margin
2096.6%
Revenue Growth YoY
—
Debt / Equity
0.89
AI Fundamental Assessment
P/E ratio of 51.4 (rich relative to a 15-40x range); Price-to-book of 14.8x; PEG ratio of -1.6 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 31.2%; Return on assets of 12.8%; Net margin of 18.4%; Gross margin of 66.8%; Current ratio of 1.80 (healthy short-term liquidity); Debt-to-equity of 0.89; Free cash flow per share is positive (6.22); Most recent quarter beat estimates by 4.7%; 5 consecutive earnings beats; EPS growth accelerating (+0.0% -> +13.9% QoQ); Average YoY EPS growth of 10.1%; Analyst estimates rising over recent quarters
Get the Full ILMN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →